Please login to the form below

Not currently logged in
Email:
Password:

Zelboraf

This page shows the latest Zelboraf news and features for those working in and with pharma, biotech and healthcare.

Roche gets FDA OKs for Alecensa and Zelboraf

Roche gets FDA OKs for Alecensa and Zelboraf

Roche gets FDA OKs for Alecensa and Zelboraf. Gains US licences for first-line use in lung cancer and a rare blood cancer. ... Meanwhile, Roche’s Zelboraf has become the first drug ever to be approved for Erdheim-Chester disease (ECD), a rare and

Latest news

More from news
Approximately 11 fully matching, plus 57 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Kite Pharma appoints Zelboraf scientist as CMO. Keith Nolop joins US cancer biotech from Plexxikon. ... Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief medical

  • AstraZeneca hires Roche’s Pascal Soriot as CEO

    This merger has spawned such drugs as cancer treatments Avastin, Herceptin and Zelboraf, and is deemed to be one of the more successful pharma deals of recent years, while during that

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics